P53, apoptosis, and breast cancer (original) (raw)

References

  1. D. P. Lane and L. V. Crawford (1979). T antigen is bound to a host protein in SV40-transformed cells.Nature 278:261–263.
    PubMed Google Scholar
  2. F. Chang, S. Syrjanen, A. Tervahauta, and K. Syrjanen (1993). Tumorigenesis associated with the p53 tumor suppressor gene.Br. J. Cancer 68:653–661.
    PubMed Google Scholar
  3. M. B. Kastan, O. Onyekwere, D. Sidransky, B. Vogelstein,R. W. Craig (1991). Participation of p53 protein in the cellular response to DNA damage.Cancer Res. 51:6304–6311.
    PubMed Google Scholar
  4. A. R. Clarke, C. A. Purdie, D. J. Harrison, R. G. Morris, C. C. Bird, M. L. Hooper, and A. H. Wyllie (1993). Thymocyte apoptosis induced by p53-dependent and independent pathways.Nature 362:849–852.
    PubMed Google Scholar
  5. D. Malkin (1994). p53 and the Li-Fraumeni syndrome.Biochim. Biophys. Acta 1198:197–213.
    PubMed Google Scholar
  6. D. Malkin, F. P. Li, L. C. Strong, J. F. Fraumeni, C. E. Nelson, D. H. Kim, J. Kassel, M. G. Gryka, F. Z. Bischoff, M. A. Tainsky, and S. H. Friend (1990). Germline p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms.Science 250:1233–1238.
    PubMed Google Scholar
  7. L. A. Donehower and A. Bradley (1993). The tumor suppressor p53.Biochim. Biophys. Acta 1155:181–205.
    PubMed Google Scholar
  8. S. M. Picksley and D. P. Lane (1994). p53 and Rb: their cellular roles.Curr. Opin. Cell Biol. 6:853–858.
    PubMed Google Scholar
  9. Y. Cho, S. Gorina, P. D. Jeffrey, and N. P. Pavletich (1994). Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations.Science 265:346–355.
    PubMed Google Scholar
  10. S. M. Picksley and D. P. Lane (1993). The p53-mdm2 autoregulatory feedback loop: a paradigm for the regulation of growth control by p53.Bioessays 15:689–690.
    PubMed Google Scholar
  11. J. D. Oliner, K. W. Kinzler, P. S. Meltzer, D. L. George, and B. Vogelstein (1992). Amplification of a gene encoding a p53 associated protein in human sarcomas.Nature 358:80–83.
    PubMed Google Scholar
  12. J. A. Pietenpol, T. Tokino, S. Thiagalingam, W. S. El-Deiry, K. W. Kinzler, and B. Vogelstein (1994). Sequence-specific transcriptional activation is essential for growth suppression by p53.PNAS 91:1998–2002.
    PubMed Google Scholar
  13. B. C. Hann and D. P. Lane (1995). The dominating effect of mutant p53.Natl. Genet. 9:221–222.
    Google Scholar
  14. D. M. Barnes, A. M. Hanby, C. E. Gillett, S. Mohammed, S. Hodgson, L. G. Bobrow, I. M. Leigh, T. Purkis, C. MacGeoch, N. K. Spurr,et al. (1992). Abnormal expression of wild type p53 protein in normal cells of a cancer family patient.Lancet 340:259–263.
    PubMed Google Scholar
  15. B. Vojtesek and D. P. Lane (1993). Regulation of p53 protein expression in human breast cancer cell lines.J. Cell Sci. 105:607–612.
    PubMed Google Scholar
  16. D. P. Lane (1992). p53, guardian of the genome.Nature 358:15–16.
    PubMed Google Scholar
  17. D. Wynford-Thomas, J. A. Bond, F. S. Wyllie, and C. J. Jones (1995). Does Telomere Shortening Drive Selection for p53 Mutation in Human Cancer?Mol. Carcinogen. 12:119–123.
    Google Scholar
  18. S. W. Lowe, H. E. Ruley, T. Jacks, and D. E. Housman (1993). p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.Cell 74:957–967.
    PubMed Google Scholar
  19. S. W. Lowe, S. Bodis, A. McClatchey, L. Remington, H. E. Ruley, D. E. Fisher, D. E. Housman, and T. Jacks (1994). p53 status and the efficacy of cancer therapy_in vivo_.Science 266:807–810.
    PubMed Google Scholar
  20. T. Fujiwara, E. A. Grimm, T. Mukhopadhyay, W. Zhang, L. B. Owen-Schaub, and J. A. Roth (1994). Induction of chemosensitivity in human lung cancer cells_in vivo_ by adenovirus-mediated transfer of the wild-type p53 gene.Cancer Res. 54:2287–2291.
    PubMed Google Scholar
  21. O. R. Koechli, G. N. Schaer, B. Seifert, R. Hornung, U. Haller, U. Eppenberger, and H. Mueller (1994). Mutant p53 protein associated with chemosensitivity in breast cancer specimens.Lancet 344:1647–1648.
    Google Scholar
  22. R. D. Petty, I. A. Cree, L. A. Sutherland, E. M. Hunter, D. P. Lane, P. E. Preece, and P. E. Andreotti (1994). Expression of the p53 tumor suppressor gene product is a determinant of chemosensitivity.Biochem. Biophys. Res. Commun. 199:264–270.
    PubMed Google Scholar
  23. D. C. Allred, G. M. Clark, S. A. W. Fuqua, R. M. Elledge, S. G. Hilsenbeck, P. M. Ravdin, D. Yee, G. C. Chamness, and C. K. Osborne (1993). Overexpression of p53 in node-positive breast cancer.Breast Cancer Res. Treat. 27:131.
    Google Scholar
  24. A. Makris, T. J. Powles, M. Dowsett, and C. Allred (1995). p53 protein overexpression and chemosensitivity in breast cancer.Lancet 345:1181–1182.
    Google Scholar
  25. M. C. Mathieu, S. Koscielny, M. L. Lebihan, M. Spielmann, and R. Arriagada (1995). p53 protein overexpression and chemosensitivity in breast cancer.Lancet 345:1182.
    Google Scholar
  26. F. J. Chang, S. Syrjanen, and K. Syrjanen (1995). Implications of the p53 tumor-suppressor gene in clinical oncology.J. Clin. Oncol. 13:1009–1022.
    PubMed Google Scholar
  27. R. Mazars, L. Spinardi, M. Bencheikh, J. Simonylafontaine, P. Jeanteur, and C. Theillet (1992). p53 mutations occur in aggressive breast cancer.Cancer Res. 52:3918–3923.
    PubMed Google Scholar
  28. J. E. Eyfjord, S. Thorlacius, M. Steinarsdottir, R. Valgardsdottir, H. M. Ogmundsdottir, and K. Anamthawat-Jonsson (1995). p53 abnormalities and genomic instability in primary human breast carcinomas.Cancer Res. 55:646–651.
    PubMed Google Scholar
  29. G. Cattoretti, F. Rilke, S. Andreola, L. D'Amato, and D. Delia (1988). p53 expression in breast cancer.Int. J. Cancer 41:178–183.
    PubMed Google Scholar
  30. C. A. Midgley, C. Fisher, J. Bartek, B. Vojtesek, D. P. Lane, and D. M. Barnes (1992). Analysis of p53 expression in human tumors: an antibody raised against human p53 expressed in_Escherichia coli_.J. Cell Sci. 101:183–189.
    PubMed Google Scholar
  31. C. J. Fisher, C. E. Gillett, B. Vojtesek, D. M. Barnes, and R. R. Millis (1994). Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.Br. J. Cancer 69:26–31.
    PubMed Google Scholar
  32. D. C. Allred, G. M. Clark, R. Elledge, S. A. W. Fuqua, R. W. Brown, G. C. Chamness, C. K. Osborne, and W. L. McGuire (1993). Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.JNCI 85:200–206.
    PubMed Google Scholar
  33. D. M. Barnes, E. A. Dublin, C. J. Fisher, D. A. Levison, and R. R. Millis (1993). Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis?Hum. Pathol. 24:469–476.
    PubMed Google Scholar
  34. T. Haerslev and G. K. Jacobsen (1995). An immunohistochemical study of p53 with correlations to histopathological parameters, c-_erb_B-2, proliferating cell nuclear antigen, and prognosis.Hum. Pathol. 26:295–301.
    PubMed Google Scholar
  35. P. A. Humphrey, D. W. Franquemont, W. A. Geary, B. Kerns, J. D. Iglehart, and J. R. Marks (1994). Immunodetection of p53 protein in noninvasive epithelial proliferative breast disease.Appl. Immunoistochem. 2:22–28.
    Google Scholar
  36. L. G. Bobrow, L. C. Happerfield, W. M. Gregory, and R. R. Millis (1995). Ductal carcinoma_in situ:_ assessment of necrosis and nuclear morphology and their association with biological markers.J. Pathol. 176:333–342.
    PubMed Google Scholar
  37. F. P. O'Malley, C. L. Vnencak-Jones, W. D. Dupont, F. Parl, S. Manning, and D. L. Page (1994). p53 mutations are confined to the comedo type ductal carcinoma_in situ_ of the breast. Immunohistochemical and sequencing data.Lab. Invest. 71:67–72.
    PubMed Google Scholar
  38. R. Holland, J. L. Peterse, R. R. Millis, V. Eusebi, D. Faverly, M. J. van de Vijver, and B. Zafrani (1994). Ductal carcinoma_in situ:_ a proposal for a new classification.Sem. Diag. Pathol. 11:167–180.
    Google Scholar
  39. B. Vojtesek, C. J. Fisher, D. M. Barnes, and D. P. Lane (1993). Comparison between p53 staining in tissue sections and p53 protein levels measured by and ELISA technique.Br. J. Cancer 67:1254–1258.
    PubMed Google Scholar
  40. A. Borg, J. Lennerstrand, M. Stenmark-Askmalm, M. Ferno, A. Brisfors, A. Ohrvik, O. Stal, D. Killander, D. Lane, and J. Brundell (1995). Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steriod receptor cytosis.Br. J. Cancer 67:1254–1258.
    Google Scholar
  41. A. M. Davidoff, B. J. M. Kerns, J. D. Iglehart, and J. R. Marks (1991). Maintenance of p53 alterations throughout breast cancer progression.Cancer Res. 51:2605–2610.
    PubMed Google Scholar
  42. J. Bartkova, J. Bartek, B. Vojtesek, J. Lukas, A. Rejthar, J. Kovarik, R. R. Millis, D. P. Lane, and D. M. Barnes (1993). Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumors.Eur. J. Cancer 29A:881–886.
    PubMed Google Scholar
  43. A. H. McCann, A. Kirley, D. N. Carney, N. Corbally, H. M. Magee, G. Keating, and P. A. Dervan (1995). Amplification of the mdm2 gene in human breast cancer and its association with mdm2 and p53 protein status.Br. J. Cancer 71:981–985.
    PubMed Google Scholar
  44. C. Cordon-Cardo, E. Latres, M. Drobnjak, M. R. Oliva, D. Pollack, J. M. Woodruff, V. Marechal, J. Chen, F. Murray, F. Brennan, and A. J. Levine (1994). Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.Cancer Res. 54:794–799.
    PubMed Google Scholar
  45. H. Patterson, S. Gill, C. Fisher, M. G. Law, H. Jayatilake, C. D. M. Fletcher, M. Thomas, R. Grimer, B. A. Gusterson, and C. S. Cooper (1994). Abnormalties of the p53 mdm2 and DCC genes in human leiomyosarcomas.Br. J. Cancer 69:1052–1058.
    PubMed Google Scholar
  46. F. P. Li, J. F. Fraumeni, J. J. Mulvihill, W. A. Blattner, M. G. Dreyfus, M. A. Tucker, and R. W. Miller (1988). A cancer family syndrome in twenty-four kindreds.Cancer Res. 48:5358–5362.
    PubMed Google Scholar
  47. J. M. Birch, A. L. Hartley, K. J. Tricker, J. Prosser, A. Condie, A. M. Kelsey, M. Harris, P. H. Morris Jones, A. Binchy, D. Crowther, A. W. Craft, O. S. Eden, G. R. Evans, E. Thompson, J. R. Mann, J. Martin, E. L. D. Mitchell, and M. F. Santibanez-Koref (1994). Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families.Cancer Res. 54:1298–1304.
    PubMed Google Scholar
  48. C. Cooper (1995) (personal communication).
  49. R. A. Eeles_et al._ (In preparation).
  50. C. MacGeoch, G. Turner, L. G. Bobrow, D. M. Barnes, D. T. Bishop, and N. K. Spurr (1995). Heterogeneity in Li-Fraumeni families: p53 mutation analysis and immunohistochemical staining.J. Med. Genet. 32:186–190.
    PubMed Google Scholar
  51. R. S. Camplejohn, P. Perry, S. V. Hodgson, G. Turner, A. Williams, C. Upton, C. MacGeoch, S. Mohammed, and D. M. Barnes (1995). A possible screening test for inherited p53-related defects based on the apoptotic reaponse of peripheral blood lymphocytes to DNA damage.Br. J. Cancer 72:654–662.
    PubMed Google Scholar

Download references